Dysregulation of miR-223, miR-146a, and miR-193a Expression Profile in Acute and Chronic Phases of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice
Cells · 2024
DOI: 10.3390/cells13171499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Saba Gharibi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University 1 Gheringhap Street, Geelong, VIC 3220, A…. Hauptthemen laut MEDLINE: MicroRNAs, Encephalomyelitis, Autoimmune, Experimental, Mice, Inbred C57BL. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple sclerosis (MS) is a chronic autoimmune disease with an unknown etiology. The purpose of this research was to assess miR-223, miR-146a, and miR-193a in acute and chronic phases of experimental autoimmune encephalomyelitis (EAE) mice to consider the possible role of these genes in the pathogenesis of MS. EAE induction was given by myelin oligodendrocyte glycoprotein peptide on female C57BL/6 mice. Clinical scores and other criteria were followed daily until day 21 for the acute group and day 77 for the chronic group. At the end of the course, inflammation and demyelination of the central nervous system (CNS) were assessed by histological analysis. MicroRNA expression levels were assessed by real-time PCR. EAE development attenuated in the chronic group, and histological analysis showed less infiltration and demyelination in the chronic group compared to the acute group. The upper expression of miR-223 is demonstrated in the acute phase of EAE. Moreover, the expression levels of miR-146a and miR-193a decreased in the chronic phase of EAE. MiR-223 showed a highly coordinated elevation in the acute phase both in vivo and in vitro. MiR-146a shares a pathway with miR-223 through effecting IL-6 expression. Further studies are needed to reveal their impact on EAE and possible applications as drug targets and biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University 1 Gheringhap Street, Geelong, VIC 3220, Australia.
- Department of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
- Research and Development Department, ROJETechnologies, Yazd, Iran.
- Department of Biology and Anatomical Sciences, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
- Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
- Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
ORCID-Profile: Dariush Haghmorad, Valentyn Oksenych
Zitieren
APA
Gharibi, S., Moghimi, B., Mahmoudi, M. B., Shahvazian, E., Yazd, E. F., Yadegari, M., Tahoori, M. T., Yazdanpanah, E., Haghmorad, D., & Oksenych, V. (2024). Dysregulation of miR-223, miR-146a, and miR-193a Expression Profile in Acute and Chronic Phases of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice. Cells. https://doi.org/10.3390/cells13171499
Vancouver
Gharibi S, Moghimi B, Mahmoudi MB, Shahvazian E, Yazd EF, Yadegari M, et al. Dysregulation of miR-223, miR-146a, and miR-193a Expression Profile in Acute and Chronic Phases of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice. Cells. 2024. doi:10.3390/cells13171499
BibTeX
@article{Gharibi2024,
author = {Gharibi, Saba and Moghimi, Bahram and Mahmoudi, Mohammad Bagher and Shahvazian, Ensieh and Yazd, Ehsan Farashahi and Yadegari, Maryam and Tahoori, Mohammad Taher and Yazdanpanah, Esmaeil and Haghmorad, Dariush and Oksenych, Valentyn},
title = {Dysregulation of miR-223, miR-146a, and miR-193a Expression Profile in Acute and Chronic Phases of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13171499}
}
EUVIMED